| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.071 | 0.1 |